Our Doctors
Scott G. Foxman, M.D.
Founder and President
Retinal and Ophthalmic Consultants, P.C.
Retina Specialist
OFFICE LOCATIONS:
1500 Tilton Road, Northfield, NJ 08225
2466 East Chestnut Avenue, Vineland, NJ 08361
211 South Main Street, Cape May Court House, NJ 08210
EDUCATION:
1973 - 1979 B.A. Boston University Medical Honors Program, Boston University
1975 - 1979 M.D. Boston University Medical Honors Program, Boston University
POSTDOCTORAL RESEARCH:
1979 National Eye Institute
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
1979 - 1980 Intern in Medicine, Jackson Memorial Hospital, Miami
1980 - 1983 Resident in Ophthalmology University of Minnesota, Minneapolis
1983 - 1985 Fellowship, Vitreo-retinal Diseases
Jules Stein Eye Institute, UCLA,
Los Angeles
FACULTY APPOINTMENT:
1983 - 1985 Visiting Lecturer Jules Stein Eye Institute University of California
1986 - Present Courtesy
Scheie Eye Institute
University of Pennsylvania
School of Medicine
1986 - 1996 Associate Attending Ophthalmologist Division of Ophthalmology
Atlantic Regional Medical Center
1997 - Present Chief, Division of Ophthalmology Atlantic Regional Medical Center
1986 - Present Assistant Attending Ophthalmologist Division of Ophthalmology Shore Memorial Hospital
SPECIALTY CERTIFICATION:
1979 - Diplomat of The National Board of Medical Examiners
1984 - Diplomat of The American Board of Ophthalmology
LICENSURE: Pennsylvania, New Jersey, California
PROFESSIONAL SOCIETIES:
| National Societies | American Society of Retina Specialists |
|
| Local Societies | Medical Society of New Jersey |
CLINICAL STAFF APPOINTMENTS
- Atlantic Regional Medical Center
- Shore Medical Center
- Betty Bacharach Rehabilitation Hospital
- Scheie Eye Institute
ACADEMIC APPOINTMENTS
- University of Penn
- Courtesy Staff
BOARD POSITIONS:
-
Past President
Atlantic County Medical Society -
Past President
Lions Club Vision Care Center
EDITORIAL POSITION:
- Business Editor
American Society of Retina Specialists
Research
SAKURA-Principal Investigator
Santen Incorporated
June 2011-Present
Protocol No. 32-007: A Phase III, Multinational, Multi-Center, Randomized,
Double-Masked Study Assessing the Safety and Efficacy of Intravitreal Injections
of DE-109 (three doses) for the Treatment of Active, Non-Infectious Uveitis of
the Posterior Segment of the Eye.
SHORE-Principal Investigator
Genentech
May 2011-Present
BB-IND 8633-Protocol FVF4967g: A Multi-Center Randomized Study
Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab
Injections in Subjects with Macular Edema Following Retinal Vein Occlusion.
April 2011-Present
VIEW 1 EXTENTION – Sub-Investigator
Regeneron
2010-Present
Open-label, long-term, safety and tolerability extension study of intravitreal VEGF Trap-Eye in neovascular age-related macular degeneration.
NAION-Principle Investigator
Covance
2009-Present
Prospective case crossover study to assess whether PDE5 inhibitor exposure in men with erectile dysfunction increases the risk for the development of non-arteritic anterior ischemic optic neuropathy (NAION).
COPERNICUS-Sub-Investigator
Regeneron
2009-Present
Randomized, Double-masked, controlled phase III study of the efficacy, safety and tolerability of repeated administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO).
HARBOR-Principle Investigator
Genetech
2009-2010
Phase III, double-masked, multi-center, randomized, active treatment, controlled study of the efficacy and safety of 0.5 mg and 2.0 mg Ranibizumab; administered monthly or on an as-needed-basis (PRN) in patients with subfoveal neovascular age-related macular degeneration.
DAVINCI- Sub-investigator
Regeneron
2008-Present
A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema (DME).
RISE - Principle Investigator
Genentech
2008 – Present
3 year multi center study with monthly visits for patients with Diabetic Macular Edema comparing Lucentis with Standard of Care Laser treatments.
CRUISE - Principle Investigator
Genentech
2008 – 2010
1 year multi center study with monthly visits comparing Lucentis to sham procedure for patients with central retinal vein occlusion.
VIEW1 - Sub-Investigator
Regeneron
2007 – Present
2 year multi center study with monthly visits comparing VEGF-Trap against Lucentis for patients with newly diagnosed age-related macular degeneration.
SIRIUS - Sub-Investigator
Allergan
2006 – 2008
2 year multi center study comparing Sirna against Lucentis for age-related macular degeneration
NOTAL VISION HMP-V4 - Sub Investigator
Notal Vision
2006-2007
Sensitivity of the Home Macular Perimeter (HMP) in detection of choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD)
SAILOR - Principal Investigator
Genentech, Inc.
2003 – 2007
1 year multi center study to evaluate the safety and tolerability of Lucentis in newly diagnosed and previously treated subjects with age-related macular degeneration.
Visudyne Photodynamic Therapy - Sub-Investigator
Ciba Vision
1999-2000
Clinical Investigator for Visudyne Photodynamic Therapy Study.
Flibanserin - Sub-Investigator
University of Pennsylvania and Boehringer Ingelheim (BI Trial No.
1997-1998
8 week, double-blind, placebo controlled Phase II study of various doses of
flibanserin and paroxetine in patients with Major Depressive Disorder. Our role was to
perform ophthalmic examinations to evaluate for potential ocular complications and side
effects.
Pioglitazone - Sub- Investigator
Takeda America, Inc.
1996
A double-blind placebo-controlled, randomized, dose-titration study to evaluate the
safety and efficacy of pioglitazone, an oral hypoglycemic agent. Our role was to perform
retinal examinations and evaluate retinal photographs for evidence of diabetic
retinopathy.
Adefovir Dipivoxil (bis-POM PMEA) - Sub - Investigator
NJCRI
1996-1997
A placebo-controlled study of the safety and efficacy of adefovir dipovoxil (bis-POM
PMEA) in prolonged survival of HIV-infected individuals with a CD4+ cell count of <
100/mm3. Our role was for ophthalmic evaluation with emphasis on the presence or
absence of CMV retinitis.
Silicone Oil - Principle Investigator
Richard James Corporation
1993-1996
Principal Investigator. Clinical investigation as to the utility and safety of silicone oil
injection in the vitreous cavity for patients with complicated retinal detachment. Our role
was to provide patient care including vitreoretinal surgery.
Perfluorocarbon Liquid - Principle Investigator
Retinal and Ophthalmic Consultants, P. C.
1992-1996
Clinical investigation as to the utility and safety of intra-operative use of perfluorocarbon
liquid into the vitreous cavity during surgical reattachment of the retina.
Sulfur hexafluoride and Perfluoropropane - Sub - Investigator
Retinal and Ophthalmic Consultants, P. C.
1989-1994
Clinical investigation as to the utility and safety of long-acting gases in the repair of
retinal detachments.
Diabetic Retinopathy
National Institutes of Health
Early Treatment of Diabetic Retinopathy Study (ETDRS)
1984-85
Dr. Scott Foxman was investigator in landmark national collaborative randomized trial of laser treatment for diabetic retinopathy.
Publications
Original Papers
-
Ballantine, E., Foxman, S., Gorden, P., Roth, J.: Rarity of Diabetic Retinopathy in Patients with Acromegaly. Arch. Intern. Med. 1981; 141:1625-1627.
-
Foxman, S., Cameron, J.D.: The Clinical Implications of Bilateral Microphthalmos with Cyst: Report of a Fatal Case. Am. J. Ophthalmol. 1984;97:632-638.
-
Foxman, S., Heckenlively, J., Bateman, J., Wirtschafter, J.: A Classifications of Congenital and Early Onset Retinitis Pigmentosa. Arch. Ophthalmol. 1985;103:1502-1506.
-
Foxman, S., Heckenlively, J., Sinclair, S.: Pigmented Paravenous Retinochoroidal Atrophy and Rubeola Retinopathy. Am. J. Ophthalmol. 1985;99:605-606.
-
Fishman, M., Kerman, B., Foxman, S.: Intraocular Cysticercus: Migratory. Ossonig, K. (ed): Proceedings of the 10th SIDUO Congress, Netherlands, W. Junk, 1986.
-
Heckenlively, J., Foxman, S., Parelhoff, E.: Retinal Dystrophy and Macular Coloboma. Doc Ophthal. 1988:68:257-271. Shields, J., Perez, N., Shields, C., Foxman, S., Foxman, B.: Simultaneous Choroidal and Brain Metastasis as Initial Manifestations of Lung Cancer. Ophthalmic Surgery and Lasers. 2002:35:323-325.
-
Foxman, S.: Finding the right fit: Considerations on both sides of the employment process. Retina Times. 2006: 24: 25-27.
-
Foxman, S.: Office Administrator: The guide of your practice’s success. Retina Times. 2006: 24: 47-51.
-
Ferencz L, Lang J, Yeshurn I, Pollack A, Siegel R, Lifshitz T, Karp J et al. Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2010 March.
-
Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators. Ranibizimab for macular edema following central retinal vein occlusion: six month primary end point results of phase III study. Ophthalmology. 2010 June; 117(6):1124-1133.e1.
Click here for additional information regarding research studies and publications by Dr. Foxman.
